MedTrace Logo

CPG 7909 Injection in Melanoma

NCT00070642 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2009-02-10

No results posted yet for this study

Summary

To determine the safety, tolerability and effects of CPG 7909 (the study drug) when given with chemotherapy to patients with melanoma.

Conditions

  • Carcinoma, Melanoma

Interventions

DRUG

CPG 7909 Injection

CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.

DRUG

dacarbazine

dacarbazine 850mg/m2 in three-week cycles until disease progression

DRUG

Chemotherapy

Chemotherapy in three-week cycles until disease progression: dacarbazine 850mg/m2

DRUG

CPG 7909 Injection

CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.

DRUG

CPG 7909 Injection

CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2005-12-31
Completion
2005-12-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00070642 on ClinicalTrials.gov